Skip to main content

Table 4 Treatment of breast events.

From: Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review

Outcome

Studies

Participants

Risk Ratio (M-H, Fixed, 95% CI), I2

Tamoxifen (20 mg daily) versus anastrozole (1 mg daily)

   

Treatment of breast events

   

   • at 3 months

Saltzstein 2005

90

0.38 (0.25, 0.58), -

Tamoxifen (10 mg daily) versus radiotherapy

   

Treatment of gynecomastia/breast pain/or both

   

   • after 9 months

Perdona 2005

35

0.21 (0.05, 0.83), -